Consensus KALA BIO, Inc.

Equities

KALA

US4831192020

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
6.3 ^USD	+1.94%		-4.40%	-10.00%

Apr. 02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
Mar. 29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on KALA BIO, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4f2da8868dff4228f900c4.VZ8gJAK00F8-3rysPb0EGYkq8h_q2Ka_Mz0fxIZ9pzw.McV5cTaFoipLm-mYfohiW9xDxEekq_f-flYqpsAT4kkZ2BdRacaDZk2X_Q~09be9e767eb37530d056933e727db392

Analyst Recommendations on KALA BIO, Inc.

HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	Apr. 02	MT
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	Nov. 17	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	Nov. 14	MT
Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating	23-08-04	MT
HC Wainwright & Co. Adjusts Price Target on Kala Pharmaceuticals to $22 From $20, Keeps Buy Rating	23-04-12	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $20 From $12, Keeps Buy Rating	23-03-06	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating	23-03-06	MT
Wedbush Raises Kala Pharmaceuticals' PT to $47 From $3 on Reduced Share Count to Account for Reverse Stock Split; Keeps Outperform Rating	22-11-09	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $2.50 From $4, Keeps Buy Rating	22-08-15	MT
Oppenheimer Adjusts Kala Pharmaceuticals' Price Target to $2 From $5, Maintains Outperform Rating	22-05-24	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $4 From $5, Keeps Buy Rating	22-05-24	MT
HC Wainwright Trims Kala Pharmaceuticals' Price Target to $5 From $6, Maintains Buy Rating	22-05-17	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $5 From $6, Reiterates Buy Rating	22-05-17	MT
Wedbush Adjusts Kala Pharmaceuticals' Price Target to $3 From $6, Keeps Outperform Rating	22-05-17	MT
Northland Capital Adjusts Kala Pharmaceuticals' Price Target to $4 from $6, Keeps Outperform Rating	22-03-30	MT
Oppenheimer Adjusts Kala Pharmaceuticals Price Target to $5 From $8, Maintains Outperform Rating	22-03-30	MT
HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $6 from $9, Keeps Buy Rating	22-03-30	MT
JPMorgan Downgrades Kala Pharmaceuticals to Underweight From Neutral; Price Target is $1.50	22-03-30	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $6 From $16 on 'Persisting Issues' Affecting Inveltys, Eysuvis Launches; Outperform Rating Kept	21-12-15	MT
Wedbush Cuts Kala Pharmaceuticals' Price Target $16 From $43, Citing Inveltys, Eysuvis Penetration Estimates; Outperform Rating Kept	21-11-16	MT
KALA PHARMACEUTICALS : Oppenheimer Adjusts Kala Pharmaceuticals PT to $13 From $15, Maintains Outperform Rating	21-10-22	MT
KALA PHARMACEUTICALS : Oppenheimer Adjusts Kala Pharmaceuticals PT to $15 From $22, Maintains Outperform Rating	21-08-06	MT
KALA PHARMACEUTICALS : HC Wainwright Adjusts Kala Pharmaceuticals' Price Target to $11 From $14, Maintains Buy Rating	21-08-06	MT
KALA PHARMACEUTICALS : JPMorgan Downgrades Kala Pharmaceuticals to Neutral From Overweight	21-08-06	MT
KALA PHARMACEUTICALS : Wedbush Adjusts Kala Pharmaceuticals' Price Target to $43 From $49, Keeps Outperform Rating	21-08-06	MT